Prednisone vs prednisone and plasma exchange (Gajdos 1983)
Score (MMS) day 30
1 finding from 1 review
- no estimate extracted1 study · 14 participantsLow
Findings
What do systematic reviews say?
17 questions · 19 findings · 5 reviews · Headline outcomes only
No studies found 2 · 10.5%GRADE not reported 2 · 10.5%Very low 3 · 15.8%Low 7 · 36.8%Moderate 4 · 21.1%High 1 · 5.3%
Prednisone vs prednisone and plasma exchange (Gajdos 1983)
Score (MMS) month 12
1 finding from 1 review
- no estimate extracted1 study · 14 participantsLow
Prednisone vs placebo or supportive treatment
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.74 [0.42, 1.32]5 studies · 746 participantsModerate
Prednisone vs placebo or supportive treatment
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.83 [0.46, 1.52]4 studies · 655 participantsModerate
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.98 [0.7, 1.36]3 studies · 487 participantsHigh
Prednisone vs placebo or supportive treatment
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.51 [0.24, 1.11]3 studies · 379 participantsModerate
Prednisone vs placebo or supportive treatment
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.06 [0.38, 2.91]3 studies · 455 participantsLow
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.39 [0.75, 2.59]2 studies · 287 participantsModerate
Prednisone vs placebo or supportive treatment
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.58 [0.42, 6]2 studies · 418 participantsLow
Prednisone vs placebo
Activity limitations ‐ not measured · people with postpolio syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Prednisone vs placebo
Adverse events · people with postpolio syndrome
1 finding from 1 review
- no estimate extracted1 study · 17 participantsGRADE not reported
Prednisone plus azathioprine vs prednisone
Disease control · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
- RR 0.93 [0.52, 1.66]1 study · 67 participantsVery low
Prednisone plus azathioprine vs prednisone
Mortality (at 6 months) · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
- RR 1.03 [0.35, 3.06]1 study · 67 participantsVery low
Prednisone plus azathioprine vs prednisone
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Prednisone plus azathioprine vs prednisone
Adverse events · bullous pemphigoid
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Oral methotrexate and oral prednisone vs prednisone or placebo
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
- RR 2.31 [1.2, 4.45]1 study · 70 participantsLow
Oral methotrexate and oral prednisone vs prednisone or placebo
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
- RR 1.23 [0.75, 2.04]1 study · 70 participantsLow
Oral methotrexate and oral prednisone vs prednisone or placebo
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
- no estimate extracted1 study · 70 participantsLow
Oral methotrexate and oral prednisone vs prednisone or placebo
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
- no estimate extracted1 study · 70 participantsGRADE not reported